A Clinical Trial to Evaluate agenT-797 Plus Standard of Care in Participants With Severe Pneumonia With Moderate to Severe Acute Hypoxemic Respiratory Failure
Condition(s) studied
Investigational drug(s) / intervention(s)
agenT-797: Intravenous infusion
Placebo: Intravenous infusion
Standard of Care (SOC): Antimicrobial therapy and corticosteroids per applicable guidelines.
Study summary
This clinical trial will evaluate the efficacy and safety of a single intravenous dose of agenT-797 administered in addition to standard of care (SOC), compared with placebo plus SOC, in reducing short-term mortality in adult participants with severe pneumonia and moderate to severe AHRF. All participants will receive SOC management for severe pneumonia and acute respiratory distress syndrome (ARDS).
Eligibility
Primary outcome measure(s)
- Number of Deaths (All-cause Mortality) — Day 1 through Day 28
Trial sites (4)
| Facility | City | Region | Status |
|---|---|---|---|
| UCSF Medical Center at Parnassus Heights | San Francisco | California | Not Yet Recruiting |
| Children's Memorial Hermann Hospital | Houston | Texas | Not Yet Recruiting |
| University Hospital | San Antonio | Texas | Not Yet Recruiting |
| First Lviv Territorial Medical Union | Lviv | Ukraine | Recruiting |
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07615010 on ClinicalTrials.gov ↗ ← All trials in the USA